← All drugs Report issue

jnj-26483327

Small moleculeexperimental

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Aug 1, 2006 (NCT00676299)

Timeline

2000s

Jan 1, 2006
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Receptor protein-tyrosine kinase erbB-2INHIBITOR
ERBB2 inhibitor
Multi-targeted tyrosine kinase inhibitor
- Receptor tyrosine-protein kinase erbB-2 (ERBB2) ↗
Receptor protein-tyrosine kinase erbB-4INHIBITOR
ERBB4 inhibitor
Multi-targeted tyrosine kinase inhibitor
- Receptor tyrosine-protein kinase erbB-4 (ERBB4) ↗
Epidermal growth factor receptor erbB1INHIBITOR
EGFR inhibitor
Multi-targeted tyrosine kinase inhibitor
- Epidermal growth factor receptor (EGFR) ↗
Vascular endothelial growth factor receptor 3INHIBITOR
FLT4 inhibitor
Multi-targeted tyrosine kinase inhibitor
- Vascular endothelial growth factor receptor 3 (FLT4) ↗
Tyrosine-protein kinase FYNINHIBITOR
FYN inhibitor
Multi-targeted tyrosine kinase inhibitor
- Tyrosine-protein kinase Fyn (FYN) ↗
Tyrosine-protein kinase LynINHIBITOR
LYN inhibitor
Multi-targeted tyrosine kinase inhibitor
- Tyrosine-protein kinase Lyn (LYN) ↗
Tyrosine-protein kinase SRCINHIBITOR
SRC inhibitor
Multi-targeted tyrosine kinase inhibitor
- Proto-oncogene tyrosine-protein kinase Src (SRC) ↗
Tyrosine-protein kinase YESINHIBITOR
YES1 inhibitor
Multi-targeted tyrosine kinase inhibitor
- Tyrosine-protein kinase Yes (YES1) ↗
Tyrosine-protein kinase LCKINHIBITOR
LCK inhibitor
Multi-targeted tyrosine kinase inhibitor
- Tyrosine-protein kinase Lck (LCK) ↗

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3

Mol. weight: 457.37 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL3545133 ↗
ChEMBLCHEMBL3109738 ↗

Also known as

jnj-26483327
jnj-26483327
jnj-26483327

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00676299	Phase 1	Aug 1, 2006	Janssen Pharmaceutica NV, Johnson and Johnson

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Janssen Pharmaceutica NV	For profit	1	0	1	2006
Johnson and Johnson	For profit	1	1	1	2006

2 organizations

Page 1 / 1